Multikinase inhibitors and uses in prostatic hyperplasia and urinary track diseases
US11376252B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 30, 2017 |
| Grant date | Jul 5, 2022 |
| Priority date | — |
| Expiry date | Mar 21, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0031
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for preventing, treating and/or improving a prostatic disease or disorder associated with epithelial hyperplasia and/or fibrosis, comprising: administering an effective amount of a multikinase inhibitor to a subject in need thereof, wherein the multikinase inhibitor has a certain spectrum of kinase inhibitory activity. The multikinase inhibitor is sunitinib, regorafenib, ponatinib, pazopanib, nintedanib and/or lenvatinib. The prostatic disease or disorder is selected from the group consisting of benign prostate hyperplasia and its associated lower urinary tract symptoms, fibrosis of ureters and renal pelvis, prostate adenoma, and prostatic intraepithelial neoplasia in animals and humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.